Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05891275 · ClinicalTrials.gov registry record
Patients With Geographic Atrophy and Their Patient Journey in the United States (US)
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 68,563
- Enrollment target
NCT05891275: Completed study, sponsored by Boehringer Ingelheim.
NCT05891275 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 68,563 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05891275 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 68,563 participants
- Enrollment target
Study Summary
To quantify and describe patients with a Geographic Atrophy (GA) diagnosis in at least one eye, and the progression to neovascular Age-Related Macular Degeneration (including how many receive Anti-VEGF), or to GA (in the fellow eye only).
Primary Outcome
Change in visual acuity (VA) in participant's study eye is reported. Study eye is defined as the first eye with the disease, and fellow eye, the participant's second eye. Change in VA was determined by calculating the difference between mean visual acuity (VA) readings at index diagnosis, and mean at another timepoint, assessed yearly for participants with valid VA readings at both timepoints.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68,563 participants |
| Start Date | 2023-05-31 |
| Est. Completion | 2023-12-01 |
What the finished NCT05891275 record still lists
NCT05891275 is an observational study that tracks outcomes without assigning an intervention. Its 68,563 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT05891275 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05891275 about?
NCT05891275 is a clinical study titled "Patients With Geographic Atrophy and Their Patient Journey in the United States (US)". To quantify and describe patients with a Geographic Atrophy (GA) diagnosis in at least one eye, and the progression to neovascular Age-Related Macular Degeneration (including how many receive Anti-VEGF), or to GA (in the fellow eye only).
What is the current status of trial NCT05891275?
This trial is currently completed. The enrollment target is 68,563 participants. The study started on 2023-05-31. Estimated completion is 2023-12-01.
Who is sponsoring clinical trial NCT05891275?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00009633 · 68,000 participants
Follow-up Visit of High Risk Infants
- NCT06903897 · 68,000 participants · NA
Social Needs Screening and Chronic Diseases Study (WE CARE)
- NCT04473833 · 65,000 participants · NA
Transvaginal Ultrasonography as a Screening Method for Ovarian Cancer
- NCT05128006 · 63,200 participants
Direct-to-patient Teledermatology and Computer-assisted Diagnosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI